title: Circulating resistin is elevated in patients with non-alcoholic fatty liver disease and is associated with steatosis, portal inflammation, insulin resistance and nonalcoholic steatohepatitis scores.
abstract: OBJECTIVE
  We aimed to investigate the association between serum levels of resistin and the biochemical and histological features of patients with nonalcoholic fatty liver disease (NAFLD) to determine the usefulness of this relationship in the clinical practice.
  
  
  METHODS
  A total of 97 patients with NAFLD and 66 age- and sex-matched healthy controls were recruited. Detailed epidemiological, anthropometric and laboratory data were recorded. Serum levels of resistin were measured with ELISA.
  
  
  RESULTS
  Serum levels of resistin were significantly higher in patients with NAFLD (32.10±10.0 ng/mL and 26.57±13.60 ng/mL, respectively) compared with healthy controls (P=0.003). Serum resistin levels were associated with AST, ALT, HOMA-IR, histological steatosis, portal inflammation and nonalcoholic steatohepatitis (NASH) scores. The serum levels of resistin were significantly higher in patients with definite NASH compared to patients with simple steatosis (29±13 and 20±10 ng/mL, respectively, P=0.03). There was no association between the serum resistin levels and the liver fibrosis stages.
  
  
  CONCLUSIONS
  Our data suggest that resistin levels are elevated in patients with NAFLD and could discriminate simple steatosis from definite NASH.
authors.affiliation: Department of Gastroenterology, Haydarpaşa Numune Education and Research Hospital, Istanbul, Turkey. ebubekirsenates@gmail.com
authors.forename: E
authors.initials: E
authors.lastname: Senateş
authors.forename: Y
authors.initials: Y
authors.lastname: Colak
authors.forename: A
authors.initials: A
authors.lastname: Yeşil
authors.forename: E
authors.initials: E
authors.lastname: Coşkunpinar
authors.forename: O
authors.initials: O
authors.lastname: Sahin
authors.forename: O T
authors.initials: OT
authors.lastname: Kahraman
authors.forename: B
authors.initials: B
authors.lastname: Erkalma Şenateş
authors.forename: I
authors.initials: I
authors.lastname: Tuncer
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D016022:Case-Control Studies; D005234:Fatty Liver / Q000097:blood* / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008099:Liver / Q000473:pathology; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease; D010689:Phlebitis / Q000097:blood; D011168:Portal System; D052243:Resistin / Q000097:blood*; D014657:Vasculitis
chemical_list: D052243:Resistin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase